Nov 16, 2020 / 01:00PM GMT
Derek Archila - Stifel Financial Corp. - Analyst
Welcome, everyone, to the 2020 Stifel Healthcare Conference. This is a day one, presentation one. I am Derek Archila. I am one of the biotech analysts here at Stifel. I am joined here by Daniel Tassé, CEO of DBV Technologies, who is going to kick us off today for the first fireside chat.
So Daniel, thanks for joining us.
Daniel Tassé,DBV Technologies S.A.-CEO
I feel honored. Thanks for having me.
Derek Archila - Stifel Financial Corp. - Analyst
Well, it's been a long year, and maybe you can give us kind of the most recent update on what you guys are working on at DBV, and then we can get into the fireside.
Daniel Tassé,DBV Technologies S.A.-CEO
As you know, DBV, has been [mainly] focusing on immunology, and particularly immunotherapy for food allergies. And our technology, essentially, has explored the human skin and epicutaneous tissues to stimulate the right
DBV Technologies SA at Stifel Virtual Healthcare Conference Transcript
Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot